The U.S. Food and Drug Administration has granted full approval for Moderna's COVID-19 vaccine, Spikevax, in children aged 6 ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...

The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Moderna's Spikevax vaccine has been fully approved for children with high-risk conditions, the first vaccine to do so.

Valued at $13 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage ...

Moderna’s experimental coronavirus vaccine was 94.5% effective at protecting people from symptomatic Covid-19, an early look at pivotal study results showed—the second vaccine to hit a key ...

U.S. National Institutes of Health scientists played "a major role" in developing Moderna Inc's COVID-19 vaccine and the agency intends to defend its claim as co-owner of patents on the shot, NIH ...

Moderna, Inc. (Nasdaq:MRNA) and Cenra Healthcare, the sales and marketing arm of Cenra Inc., today announced that the companies have entered into a joint agreement regarding the co-promotion of ...

Moderna is in the midst of a cancer treatment and vaccine "revolution," according to its CEO who joined "Mornings with Maria" on Wednesday to discuss its latest advancement with health care ...